Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma
In metastatic clear-cell renal cell carcinoma (mccRCC), choosing between immuno-oncology (IO) combinations and IO plus anti-VEGF therapies is uncertain. The BIONIKK trial revealed that ipilimumab plus nivolumab (Ipi/Nivo) achieved a 70% objective response rate in angiogenic cluster1/2 versus 41% in cluster4/5, which featured T-effector/cell-cycle signatures (p = 0.048). Complete responses were exclusively observed in cluster1/2 (p = 0.012), with longer progression-free survival (p = 0.014). Ipi/Nivo may particularly benefit angiogenic mccRCC, supporting molecular subtype-based treatment strategies.
Authors
- Virginie Verkarre (ORCID: https://orcid.org/0000-0001-7720-0236)
- Yann Vano (ORCID: https://orcid.org/0000-0002-9410-1368)
- Xiaofan Lu (ORCID: https://orcid.org/0000-0003-2417-6548)
- Wenxuan Cheng (ORCID: https://orcid.org/0000-0002-6854-6769)
- Li Xu (ORCID: https://orcid.org/0000-0002-8450-8914)
- Catherine Sautès‐Fridman (ORCID: https://orcid.org/0000-0003-1735-8722)
- Cheng‐Ming Sun (ORCID: https://orcid.org/0000-0002-2392-7701)
- Stéphane Oudard (ORCID: https://orcid.org/0000-0003-0893-285X)
- Gabriel G. Malouf (ORCID: https://orcid.org/0000-0003-3527-0417)
- Xiaoping Su (ORCID: https://orcid.org/0000-0003-1824-943X)
- Wolf H. Fridman (ORCID: https://orcid.org/0000-0002-1332-0973)
- Salma Kotti
- Fangrong Yan (ORCID: https://orcid.org/0000-0003-3347-5021)
Institutions
- Centre National de la Recherche Scientifique (FR)
- The University of Texas MD Anderson Cancer Center (US)
- Inserm (FR)
- China Pharmaceutical University (CN)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Sorbonne Paris Cité (FR)
- Centre de Recherche des Cordeliers (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Européen (FR)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1038/s41698-025-00912-x
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fondation ARC pour la Recherche sur le Cancer